ReviewSteroids2008
Challenges to defining a role for progesterone in breast cancer.
Review in Steroids, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 68 citations in OpenAlex.
- Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Breast Cancer Histopathology in the Age of Molecular Oncology.Cold Spring Harbor perspectives in medicine · 2024Review
- Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer.Frontiers in endocrinology · 2024Article
- CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women.Cancer biomarkers : section A of Disease markers · 2022Article
- CmPn signaling networks in the tumorigenesis of breast cancer.Frontiers in endocrinology · 2022Article
- Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.Frontiers in endocrinology · 2021Review
- Molecular Subtypes and Local-Regional Control of Breast Cancer.Surgical oncology clinics of North America · 2018Review
- Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden Maternity Cohort.Breast cancer research : BCR · 2017Article
- The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer.Oncotarget · 2017Article
- Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.ESMO open · 2016Article
- Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry.Hormone molecular biology and clinical investigation · 2015Article
- Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor.Endocrine · 2015Article
- Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.Cancer immunology, immunotherapy : CII · 2013Article
- Epimorphin is a novel regulator of the progesterone receptor isoform-a.Cancer research · 2013Article
- Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.Oncogene · 2013Article
- The therapeutic target Hsp90 and cancer hallmarks.Current pharmaceutical design · 2013Review
- Stimulation of GPR30 increases release of EMMPRIN-containing microvesicles in human uterine epithelial cells.The Journal of clinical endocrinology and metabolism · 2012Article
- Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel.Molecular and cellular endocrinology · 2012Article
- From the ranks of mammary progesterone mediators, RANKL takes the spotlight.Molecular and cellular endocrinology · 2012Review
- Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.Breast cancer research : BCR · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Progesterone is an ovarian steroid hormone that is essential for normal breast development during puberty and in preparation for lactation. The actions of progesterone are primarily mediated by its high affinity receptors, including the classical progesterone receptor (PR) -A and -B isoforms, located in diverse tissues such as the brain where progesterone controls reproductive behavior, and the breast and reproductive organs. Progestins are frequently prescribed as contraceptives or to alleviate menopausal symptoms, wherein progestin is combined with estrogen as a means to block estrogen-induced endometrial growth. Estrogen is undisputed as a potent breast mitogen, and inhibitors of the estrogen receptor (ER) and estrogen producing enzymes (aromatases) are effective first-line cancer therapies. However, PR action in breast cancer remains controversial. Herein, we review existing evidence from in vitro and in vivo models, and discuss the challenges to defining a role for progesterone in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.